Viking Therapeutics, Inc. (VKTX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Diego, CA, アメリカ. 現CEOは Brian Lian.
VKTX を有する IPO日 2015-04-28, 45 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $4.1B.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for metabolic and endocrine disorders. The company's lead candidate, VK2809, is an orally available thyroid hormone receptor beta agonist currently in Phase IIb trials for non-alcoholic steatohepatitis and fatty liver disease. Viking's pipeline also includes VK5211, a selective androgen receptor modulator in Phase II development for hip fracture recovery; VK0612, a Phase IIb-ready candidate for type 2 diabetes; and VK0214, another thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Founded in 2012, the company focuses on addressing significant unmet medical needs in metabolic and endocrine disease treatment.
